Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy

Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, and Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss key updates in myeloproliferative neoplasms (MPNs) presented at the 2022 ASH Annual Meeting. Dr Gerds and Dr Masarova first comment on clinical trial updates, drawing focus on the MOMENTUM trial (NCT04173494), and then go on to highlight the importance of investigating combination approaches versus monotherapy in MPNs. Following this, the experts highlight the importance of sequencing therapies and improving biomarkers to monitor disease progression and patient response to therapy. To conclude, Dr Gerds and Dr Masarova discuss exciting novel agents in the field, including JAK inhibitors, combination therapy with ruxolitinib, and the potential role of calreticulin-targeting antibodies, and further comment on unmet needs in the treatment of blast-phase MPNs (BP-MPNs). This discussion took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.